Replimune Group is a clinical-stage biotechnology company pioneering oncolytic immunotherapies to transform cancer treatment. Its lead candidate, RP1, is engineered to directly destroy tumors while activating a systemic immune response. Used in combination with checkpoint inhibitors, it benefits patients with advanced solid tumors, including melanoma and skin cancers, offering hope where standard therapies have failed.
Get alerts when this topic surges in newsletters. Free to start.
Sign up freeExplore more trends:Trending Topics ·AI Trends ·Business Trends ·Finance Trends ·Technology Trends